Myasthenia gravis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 13
• BCMA 13
• CD20 3
• PD-1 0
• CD40 0
• JAK 0
• AKT 0
• HIF-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• AMPK 0
• AQP4 1
• COX-2 0
• GPX4 0
• HER2 0
• HMGB1 0
• IL-1 0
• IL-6 0
• MAPK 0
• NLRP3 0
• PD-L1 0
• PSMA 0
• SGLT2 0
• STAT3 0
• STING 0

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  REPROGRAMMING IMMUNITY FOR A BRIGHTER FUTURE FOR AUTOIMMUNE PATIENTS (ADCure)

  Canopy Immuno-Therapeutics Ltd· Megadim, Israel· EU contribution €2,430,249· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Understanding and targeting pathogenic IgG4 responses (IGG4-START)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €1,493,090· until Dec 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Systematic study of IgG4-autoimmune diseases to develop new treatment strategies (IgG4-TREAT)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €2,626,812· until Aug 2027· 9 countries

3 of 3 running projects, newest first. Listed amounts together: €6.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

  NCT06220201· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

  NCT06371040· Ting Chang, MD· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 9
• Gene Expression Profiling 6
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 6
• Flow Cytometry 4
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 8
• Cohort Studies 37
• Genome-Wide Association Study 10

• Identification of rs28362336 as a risk SNP for generalized myasthenia gravis and its impact on HCG27 regulation.

  PLoS One, Sept 2026

• Associations of Weight and Glucose Levels With Myasthenia Gravis: A Two-Step, Two-Sample Mendelian Randomization and Retrospective Case-Control Study.

  Brain Behav, Sept 2026

• Genome-Wide and Locus-Level Analyses Reveal Modest, Heterogeneous Genetic Sharing Between Alzheimer's Disease and Myasthenia Gravis.

  Int J Mol Sci, May 2026

• CFD+CD14+ monocytes: potential pathogenic subset in myasthenia gravis uncovered by multi-omics integration and machine learning analysis.

  Front Immunol, May 2026

• Shared genetic and neuroimmune architecture links type 1 diabetes with neurocognitive traits.

  Nat Commun, Mar 2026

• Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

  Nat Commun, Mar 2026

• Genetic insights into biological aging and myasthenia gravis: a Mendelian randomization study of telomere length, epigenetic clocks, and mitochondrial DNA copy number.

  Clin Epigenetics, Feb 2026

• Exploring the Role of B-Cell Biotherapy in Myasthenia Gravis from a Genetic Perspective: A Mendelian Randomization Study.

  Mol Neurobiol, Nov 2025

• Mitochondrial proteins contribute to the pathogenesis of myasthenia gravis.

  Sci Rep, Nov 2025

• Assessing the potential causal influence of myasthenia gravis on neurodegenerative diseases via multivariable Mendelian randomization.

  Medicine (Baltimore), Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.